tiprankstipranks
Trending News
More News >
Acrux Limited (ARUXF)
OTHER OTC:ARUXF

Acrux (ARUXF) Price & Analysis

Compare
4 Followers

ARUXF Stock Chart & Stats

$0.01
<$0.01(41.59%)
At close: 4:00 PM EST
$0.01
<$0.01(41.59%)

Acrux News

ARUXF FAQ

What was Acrux Limited’s price range in the past 12 months?
Acrux Limited lowest stock price was <$0.01 and its highest was $0.05 in the past 12 months.
    What is Acrux Limited’s market cap?
    Acrux Limited’s market cap is $4.11M.
      When is Acrux Limited’s upcoming earnings report date?
      Acrux Limited’s upcoming earnings report date is Mar 03, 2026 which is in 69 days.
        How were Acrux Limited’s earnings last quarter?
        Acrux Limited released its earnings results on Aug 28, 2025. The company reported -$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.004.
          Is Acrux Limited overvalued?
          According to Wall Street analysts Acrux Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Acrux Limited pay dividends?
            Acrux Limited pays a Annually dividend of $0.063 which represents an annual dividend yield of N/A. See more information on Acrux Limited dividends here
              What is Acrux Limited’s EPS estimate?
              Acrux Limited’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does Acrux Limited have?
              Acrux Limited has 410,608,520 shares outstanding.
                What happened to Acrux Limited’s price movement after its last earnings report?
                Acrux Limited reported an EPS of -$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
                  Which hedge fund is a major shareholder of Acrux Limited?
                  Currently, no hedge funds are holding shares in ARUXF
                  What is the TipRanks Smart Score and how is it calculated?
                  Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                    Acrux Stock Smart Score

                    3
                    Underperform
                    1
                    2
                    3
                    4
                    5
                    6
                    7
                    8
                    9
                    10

                    Fundamentals

                    Return on Equity
                    -270.27%
                    Trailing 12-Months
                    Asset Growth
                    -18.83%
                    Trailing 12-Months

                    Company Description

                    Acrux Limited

                    Acrux Limited, together with its subsidiaries, develops and commercializes generic and topical pharmaceuticals in Australia, Europe, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of adult males who have low or no testosterone. It also provides estradiol sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause. The company was incorporated in 1998 and is based in West Melbourne, Australia.

                    Acrux (ARUXF) Earnings & Revenues

                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Living Cell Technologies
                    Invex Therapeutics Ltd.
                    Chimeric Therapeutics Ltd.
                    Neuroscientific Biopharmaceuticals Ltd.
                    Memphasys Ltd

                    Ownership Overview

                    5.19%94.81%
                    ― Other Institutional Investors
                    94.81% Public Companies and
                    Individual Investors

                    Options Prices

                    Currently, No data available
                    ---
                    Popular Stocks